Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 651-658

  Baririan, Nariné ^a   Chanteux, Hugues ^a   Viaene, Eric ^a   Servais, Hélène ^a   Tulkens, Paul M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Compatibility; Continuous infusion; Degradation; Stability

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DOBUTAMINE; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; KETAMINE; MIDAZOLAM; MORPHINE; NICARDIPINE; PHENYTOIN; PIRITRAMIDE; PROPOFOL; REMIFENTANIL; SEDATIVE AGENT; SUFENTANIL; THEOPHYLLINE; TOBRAMYCIN; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN;

ARTICLE; CONTAINER; CONTINUOUS INFUSION; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG INCOMPATIBILITY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUTION; DRUG STABILITY; HUMAN; INFUSION PUMP; INTENSIVE CARE UNIT; OUTPATIENT CARE; PH MEASUREMENT; SIDE EFFECT; TEMPERATURE MEASUREMENT; TREATMENT INDICATION;

AMBULATORY CARE; CEFTAZIDIME; CEPHALOSPORINS; CYSTIC FIBROSIS; DRUG INCOMPATIBILITY; DRUG STABILITY; DRUG STORAGE; DRUG THERAPY, COMBINATION; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; PRECIPITATION;

EID: 0037339053     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg134     Document Type: Article

References (39)

1. Karchmer, A. W. (2000). Cephalosporins. In Principles and Practice of Antiinfectious Diseases (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 274-88. Churchill Livingstone, Philadelphia, PA, USA.
2. Dagan, R., Leibovitz, E., Greenberg, D., Yagupsky, P., Fliss, D. M. & Leiberman, A. (1998). Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatric Infectious Disease Journal 17, 776-82.
3. Gustafsson, I., Lowdin, E., Odenholt, 1. & Cars, O. (2001). Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrobial Agents and Chemotherapy 45, 2436-40.
4. Craig, W. A. & Ebert, S. C. (1992). Continuous infusion of beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy 36, 2577-83.
5. McNabb, J. J., Nightingale, C. H., Quintiliani, R. & Nicolau, D. P. (2001). Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 21, 549-55.
6. Vinks, A. A., Brimicombe, R. W., Heijerman, H. G. & Bakker, W. (1997). Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. Journal of Antimicrobial Chemotherapy 40, 125-33.
7. Rappaz, I., Decosterd, L. A., Bille, J., Pilet, M., Belaz, N. & Roulet, M. (2000). Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. European Journal of Pediatrics 159, 919-25.
8. Lipman, J., Gomersall, C. D., Gin, T., Johnt, G. M. & Young, R. J. (1999). Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 43, 309-11.
9. Okomoto, M. P., Nakahiro, R. K., Chin, A. & Bedikian, A. (1993). Cefepime clinical pharmacokinetics. Clinical Pharmacokinetics 25, 88-102.
10. Pucci, M. J., Boice-Sowek, J., Kessler, R. E. & Dougherty, T. J. (1991). Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrobial Agents and Chemotherapy 35, 2312-7.
11. Chong, Y., Lee, K. & Kwon, O. H. (1993). In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic Gram-negative bacilli. Journal of Antimicrobial Chemotherapy 32, Suppl. B, 21-9.
12. Thornsberry, C., Brown, S. D., Yee, Y. C., Bouchillon, S. K., Marler, J. K. & Rich, T. (1993). In-vitro activity of cefepime and other antimicrobials: survey of European isolates. Journal of Antimicrobial Chemotherapy 32, Suppl. B, 31-53.
13. Jacoby, G. A. & Carreras, I. (1990). Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrobial Agents and Chemotherapy 34, 858-62.
14. Burgess, D. S., Hastings, R. W. & Hardin, T. C. (2000). Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clinical Therapeutics 22, 66-75.
15. Georges, B., Archambaud, M., Saivin, S., Decun, J. F., Cougot, P., Mazerolles, M. et al. (1999). Infusion continue versus administration intermittente du céfépime. Résultats préliminaires [Continuous versus intermittent cefepime infusion in critical care. Preliminary results]. Pathologie-Biologie 47, 483-5.
16. Viaene, E., Chanteux, H., Servais, H., Mingeot-Leclercq, M.-P. & Tulkens, P. M. (2002). Comparative stability studies of anti-pseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrobial Agents and Chemotherapy 46, 2327-32.
17. Fubara, J. O. & Notari, R. E. (1998). Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions. Journal of Pharmaceutical Sciences 87, 1572-6.
18. Anonymous. (2001). Compendium 2001, 19th edn. Association Générale de l'Industrie du Médicament a.s.b.l., MediMedia Belgium, Brussels, Belgium.
19. Calahorra, B., Campanero, M. A., Sadaba, B. & Azanza, J. R. (1999). Rapid high-performance liquid chromatographic determination of cefepime in human plasma. Biomedical Chromatography 13, 272-5.
20. Anonymous. (1995). Ceftazidime for injection. In The United States Pharmacopeia/The National Formulary, pp. 310-1. United States Pharmacopeial Convention, Inc., Rockville, MD, USA.
21. Page, M. I. (1992). The Chemistty of Beta-Lactams. Blackie Academic and Professional, London, UK.
22. Farina, A., Porra, R., Cotichini, V. & Doldo, A. (1999). Stability of reconstituted solutions of ceftazidime for injections: an HPLC and CE approach. Journal of Pharmaceutical and Biomedical Analysis 20, 521-30.
23. Servais, H. & Tulkens, P. M. (2001). Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrobial Agents and Chemotherapy 45, 2643-7.
24. Rabouan-Guyon, S., Guet, A. S., Courtois, P. Y. & Barthes, D. M. C. (1997). Stability study of cefepime in different infusion solutions. International Journal of Pharmaceutics 154, 185-90.
25. Stewart, J. T., Warren, F. W., Johnson, S. M., Fox, J. L. & Mullaney, J. (1992). Stability of ceftazidime in plastic syringes and glass vials under various storage conditions. American Journal of Hospital Pharmacy 49, 2765-8.
26. Stiles, M. L., Allen, L. V., Jr & Fox, J. L. (1992). Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. American Journal of Hospital Pharmacy 49, 2761-4.
27. Stewart, J. T., Warren, F. W. & Maddox, F. C. (1999). Stability of cefepime hydrochloride injection in polypropylene syringes at -20°C, 4°C, and 22-24°C. American Journal of Health-System Pharmacy 56, 457-9.
28. Sprauten, P., Beringer, P., Gill, M., Louie, S. & Synold, T. (2002). Temperature stability and antibacterial activity of cefepime during continuous infusion administration. In Program and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 2002. Abstract A-1400, p.21. American Society for Microbiology, Washington, DC, USA.
29. Anonymous. (1999). Physicians' Desk Reference, 53rd edn. Medical Economics Company, Inc., Montvale, NJ, USA.
30. Bugnon, D., Giannoni, E., Majcherczyk, P., Glauser, M. P. & Moreillon, P. (2002). Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro. Antimicrobial Agents and Chemotherapy 46, 3654-6.
31. Anonymous. (2001). http://www.epa.gov/opprd001/inerts/list3-inerts.pdf (21 July 2002, date last assessed). Environmental Protection Agency, Washington, DC, USA.
32. Anonymous. (1999). Register of flavouring substances. Official Journal of the European Communities L84, 1-74.
33. Forgue, S. T., Kari, P. & Barbhaiya, R. (1987). N-oxidation of N-methylpyrrolidine released in vivo from cefepime. Drug Metabolism and Disposition 15, 808-15.
34. Goto, A., Amano, M., Sakai, A., Hara, M. & Takahashi, N. (1992). General pharmacology of cefepime (original title in Japanese). Japanese Journal of Antibiotics 45, 661-80.
35. Barbhaiya, R. H., Knupp, C. A., Forgue, S. T., Matzke, G. R., Halstenson, C. E., Opsahl, J. A. et al. (1991). Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metabolism and Disposition 19, 68-73.
36. Dixit, S., Kurle, P., Buyan-Dent, L. & Sheth, R. D. (2000). Status epilepticus associated with cefepime. Neurology 54, 2153-5.
37. Vaughan, L. M. & Poon, C. Y. (1994). Stability of ceftazidime and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution. Annals of Pharmacotherapy 28, 572-6.
38. Anonymous. (2000). Ceftazidime. In Pharmacopée Européenne, pp. 2909-11. European Directorate for the Quality of Medicines (EDQM) of the Council of Europe, Strasbourg, France.
39. Anonymous. (1996). Note for Guidance on Manufacture of the Finished Dosage Form (CPMP/QWP/486/95). pp. 1-6. The European Agency for the Evaluation of Medicinal Products (EMEA), London, UK.